Loading
New York melanoma doctor who was lead author of BRIM-3, the trial that showed vemurafenib lengthens survival in BRAF-mutant melanoma and launched targeted therapy for the disease.
Paul Chapman is a melanoma medical oncologist at Memorial Sloan Kettering Cancer Center. He was first author of the 2011 New England Journal of Medicine report of BRIM-3, the phase 3 trial in which the BRAF inhibitor vemurafenib improved overall and progression-free survival compared with dacarbazine in previously untreated BRAF V600E-mutant metastatic melanoma, the first targeted drug to do so in the disease.
| Title | Journal | Year |
|---|---|---|
| BRIM-3: improved survival with vemurafenib in melanoma with BRAF V600E mutation | New England Journal of Medicine | 2011 |
Shares BRAF V600-mutant melanoma, Melanoma and the tags melanoma, trialist.
Shares BRAF V600-mutant melanoma, Melanoma and the tags melanoma, trialist.
Shares Memorial Sloan Kettering Cancer Center and the tags targeted-therapy, trialist.
Shares Memorial Sloan Kettering Cancer Center and the tags targeted-therapy, trialist.
Shares Melanoma and the tags melanoma, trialist.
Shares Memorial Sloan Kettering Cancer Center and the tags targeted-therapy, trialist.
Shares Melanoma and the tags melanoma, trialist.
Shares Melanoma and the tags melanoma, targeted-therapy.